4.8 Article

Site- and allele-specific polycomb dysregulation in T-cell leukaemia

期刊

NATURE COMMUNICATIONS
卷 6, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms7094

关键词

-

资金

  1. la Fondation pour la Recherche Medicale [INE2003114116]
  2. Le Conseil General des Bouches du Rhone, le Canceropole PACA, CALYM consortium, l'Institut National du Cancer [INCa PLBIO09]

向作者/读者索取更多资源

T-cell acute lymphoblastic leukaemias (T-ALL) are aggressive malignant proliferations characterized by high relapse rates and great genetic heterogeneity. TAL1 is amongst the most frequently deregulated oncogenes. Yet, over half of the TAL1(+) cases lack TAL1 lesions, suggesting unrecognized (epi) genetic deregulation mechanisms. Here we show that TAL1 is normally silenced in the T-cell lineage, and that the polycomb H3K27me3-repressive mark is focally diminished in TAL1(+) T-ALLs. Sequencing reveals that >20% of monoallelic TAL1(+) patients without previously known alterations display microinsertions or RAG1/2-mediated episomal reintegration in a single site 50 to TAL1. Using 'allelic-ChIP' and CrispR assays, we demonstrate that such insertions induce a selective switch from H3K27me3 to H3K27ac at the inserted but not the germline allele. We also show that, despite a considerable mechanistic diversity, the mode of oncogenic TAL1 activation, rather than expression levels, impact on clinical outcome. Altogether, these studies establish site-specific epigenetic desilencing as a mechanism of oncogenic activation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Long-term outcome of paediatric anti-N-methyl-D-aspartate receptor encephalitis

Lorraine Flet-Berliac, Nicolas Tchitchek, Anne Lepine, Anca Florea, Helene Maurey, Pascale Chretien, Salima Hacein-Bey-Abina, Frederic Villega, Emmanuel Cheuret, Veronique Rogemond, Geraldine Picard, Jerome Honnorat, Kumaran Deiva

Summary: This French study aimed to investigate the long-term clinical and cognitive outcomes of patients with anti-N-methyl-D-aspartate receptor encephalitis (NMDAR-E). The study found that more than 45% of patients experienced cognitive and academic difficulties, and the severity of symptoms seemed to have an impact on cognition and academic performances.

DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2023)

Article Oncology

PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma

David Jeremie Birnbaum, Maelle Picard, Quentin Da Costa, Thomas Delayre, Pascal Finetti, Olivier Cabaud, Emilie Agavnian, Bernadette De Rauglaudre, Emilie Denicolai, Francois Bertucci, Emilie Mamessier

Summary: Hepatocellular carcinoma (HCC) is a common and deadly cancer, and new treatments are needed. Immune checkpoint inhibitors (ICIs) have shown promise for HCC. By analyzing a large transcriptomic database, we found that the TIGIT/DNAM-1 axis, particularly the PVRIG molecule, could be a potential therapeutic option for HCC.

CANCERS (2023)

Article Immunology

Selective STING stimulation in dendritic cells primes antitumor T cell responses

Bakhos Jneid, Aurore Bochnakian, Caroline Hoffmann, Fabien Delisle, Emeline Djacoto, Philemon Sirven, Jordan Denizeau, Christine Sedlik, Yohan Gerber-Ferder, Frederic Fiore, Ramazan Akyol, Carine Brousse, Robert Kramer, Ian Walters, Sylvain Carlioz, Helene Salmon, Bernard Malissen, Marc Dalod, Eliane Piaggio, Nicolas Manel

Summary: Activation of STING in immunogenic tumors can induce antitumor T cell response, but it remains unclear how to apply it in nonimmunogenic tumors. This study showed that intratumoral delivery of cGAMP-VLP activated T cells and reduced tumor regulatory T cells, synergizing with PD1 blockade. However, intratumoral administration of the synthetic CDN ADU-S100 caused tumor necrosis and systemic T cell activation, but depleted immune cells and minimally primed circulating tumor-specific T cells. Thus, cell targeting of STING stimulation shapes the antitumor T cell response and provides a strategy to enhance T cell-targeted immunotherapy.

SCIENCE IMMUNOLOGY (2023)

Article Biology

PTPN22 R620W gene editing in T cells enhances low-avidity TCR responses

Warren Anderson, Fariba Barahmand-pour-Whitman, Peter S. Linsley, Karen Cerosaletti, Jane H. Buckner, David J. Rawlings, Bernard Malissen

Summary: A genetic variant in the PTPN22 gene increases the risk for multiple autoimmune diseases and affects T cell regulation and activation. Using gene editing, researchers created T cells with different PTPN22 variants and found that the risk variant and PTPN22 knockout both led to increased T cell activation. They also observed enhanced signaling and proliferation in T cells with self-reactive T cell receptors lacking PTPN22 function. These findings suggest that PTPN22 rs2476601 contributes to autoimmunity risk by promoting TCR signaling and activation in mildly self-reactive T cells.
Article Oncology

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

Clemence Demerle, Laurent Gorvel, Marielle Mello, Sonia Pastor, Clara Degos, Ana Zarubica, Fabien Angelis, Frederic Fiore, Jacques A. Nunes, Bernard Malissen, Laurent Greillier, Geoffrey Guittard, Herve Luche, Fabrice Barlesi, Daniel Olive

Summary: The study found that anti-HVEM18-10 can enhance the activity of human αβ-T cells and trigger T cell activation in the presence of PD-L1-negative cells. Anti-HVEM18-10 treatment inhibits the growth of HVEM-positive tumors in mouse models and promotes the presence of effector memory CD4+ T cells while suppressing exhausted CD8+ T cells and regulatory T cells.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Biology

An OMA1 redox site controls mitochondrial homeostasis, sarcoma growth, and immunogenicity

Richard Miallot, Virginie Millet, Yann Groult, Angelika Modelska, Lydie Crescence, Sandrine Roulland, Sandrine Henri, Bernard Malissen, Nicolas Brouilly, Laurence Panicot-Dubois, Renaud Vincentelli, Gerlind Sulzenbacher, Pascal Finetti, Aurelie Dutour, Jean-Yves Blay, Francois Bertucci, Franck Galland, Philippe Naquet

Summary: Aggressive tumors often have dysfunctional mitochondria. OMA1 mediates fission of mitochondria in response to oxidative stress through cleavage of the fusion effector OPA1. In this study, mutation of cysteine 403 in OMA1 impaired mitochondrial responses to stress, resulting in reduced ATP production, resistance to apoptosis, and enhanced mitochondrial DNA release. Inactivation of OMA1 increased anti-tumor immunity and may enhance sarcoma immunogenicity.

LIFE SCIENCE ALLIANCE (2023)

Article Immunology

Defective LAT signalosome pathology in mice mimics human IgG4-related disease at single-cell level

Anais Joachim, Rudy Aussel, Lena Gelard, Fanghui Zhang, Daiki Mori, Claude Gregoire, Sergio Villazala Merino, Mauro Gaya, Yinming Liang, Marie Malissen, Bernard Malissen

Summary: Mice with a loss-of-function mutation in the LAT adaptor (Lat(Y136F)) develop an autoimmune and type 2 inflammatory disorder called defective LAT signalosome pathology (DLSP). Through single-cell omics analysis, it was found that T follicular helper cells, CD4+ cytotoxic T cells, activated B cells, and plasma cells are present in Lat(Y136F) spleen and lung. This cell constellation is similar to the cell types involved in IgG4-related disease (IgG4-RD), indicating that Lat(Y136F) DLSP can serve as a model for IgG4-RD.

JOURNAL OF EXPERIMENTAL MEDICINE (2023)

Article Biology

The coenzyme A precursor pantethine enhances antitumor immunity in sarcoma

Richard Miallot, Virginie Millet, Anais Roger, Romain Fenouil, Catherine Tardivel, Jean-Charles Martin, Laetitia Shintu, Paul Berchard, Juliane Sousa Lanza, Bernard Malissen, Sandrine Henri, Sophie Ugolini, Aurelie Dutour, Pascal Finetti, Francois Bertucci, Jean-Yves Blay, Franck Galland, Philippe Naquet

Summary: The study found that pantethine can inhibit tumor growth by enhancing the function of the immune system. Pantethine can promote the polarization of myeloid and dendritic cells towards enhanced antigen presentation pathways and improve the development of CD8+ T cells with immune effector activity. However, immune cell exhaustion limits the therapeutic effect of pantethine.

LIFE SCIENCE ALLIANCE (2023)

Meeting Abstract Oncology

A preclinical platform of breast cancer PDX and derived cellular models as a tool for pharmacological screening and functional studies

Delphine Nicolle, Aurore Gorce, Marie Tavernier, Elisabetta Marangoni, Didier Decaudin, Christophe Ginestier, Emmanuelle Charafe-Jaufret, Judith Passildas, Nina Robin, Robert Clarke, Erwan Corcuff, Anais Joachim, Bernard Malissen, Ana Zarubica, Herve Luche, Jean-Gabriel Judde, Olivier Deas

CANCER RESEARCH (2023)

Meeting Abstract Oncology

Deep Immuno-profiling of syngeneic tumor mouse models for preclinical studies

Anais Joachim, Emilie Maturin, Marielle Mello, Lillia Hadjem, Magali Grange, Olivier Deas, Ana Zarubica, Bernard Malissen, Herve Luche

CANCER RESEARCH (2023)

Meeting Abstract Oncology

Systematic immune-profiling of immune-deficient mouse models: A rational to select ideal host for tumor implantation

Herve Luche, Lillia Hadjem, Marielle Mello, Priscilla Canavese, Fabien Angelis, Anais Joachim, Sylvie Bouilly, Frederic Guinut, Frederic Fiore, Bernard Malissen, Ana Zarubica, Erwan Corcuff

CANCER RESEARCH (2023)

Meeting Abstract Oncology

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

Laurent Gorvel, Clemence Demerle, Marielle Mello, Sonia Pastor, Clara Degos, Ana Zarubica, Fabien Angelis, Frederic Fiore, Jacques Nunes, Bernard Malissen, Laurent Greillier, Geoffrey Guittard, Herve Luche, Fabrice Barlesi, Daniel Olive

CANCER RESEARCH (2023)

Article Immunology

A dual function for the chromatin organizer Special A-T rich Binding Protein 1 in B-lineage cells

Morgane Thomas, Charlotte Bruzeau, Ophelie Alyssa Martin, Justine Pollet, Sebastien Bender, Claire Carrion, Sandrine Le Noir, Eric Pinaud

Summary: SATB1 is a cell type-specific factor that plays an essential role in the genetic network of developing T cells and neurons. However, its involvement in B-cell differentiation needs further clarification. Our study using a SATB1 knockout mouse model reveals that SATB1 is dispensable for B-cell development and the establishment of a broad IgH repertoire. We also find that SATB1 has a dual function in mature B cells, acting as a positive regulator in naive cells and a negative regulator in activated cells.

CELLULAR & MOLECULAR IMMUNOLOGY (2023)

Article Hematology

Single-cell analysis of megakaryopoiesis in peripheral CD34+ cells: insights into ETV6-related thrombocytopenia

Elisa Gabinaud, Laurent Hannouche, Elisa Andersen, Delphine Bastelica, Denis Bernot, Manal Ibrahim-Kosta, Pierre-Emmanuel Morange, Marie Loosveld, Paul Saultier, Dominique Payet-Bornet, Marie-Christine Alessi, Delphine Potier, Marjorie Poggi

Summary: Using single-cell RNA sequencing, researchers have discovered a link between ETV6 germline mutations and thrombocytopenia through the highly deregulated core ribosome biogenesis pathway.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

暂无数据